Dermatology Book

Hair Disorders


Eflornithine Cream

Aka: Eflornithine Cream, Vaniqa
  1. Indications
    1. Hirsutism: Removal of unwanted facial hair in women
  2. Pharmacology
    1. Irreversible inhibitor of ornithine decarboxylase
      1. Inhibits polyamine biosynthesis
      2. Decreases polyamine mediated cell division
    2. Prior systemic use for African Trypanosomiasis
    3. Peak systemic absorption <10 ng/ml
  3. Adverse Effects: Local irritation
    1. Stinging or burning
    2. Tingling
  4. Dosing (30 gram tube costs pharmacist $42)
    1. Apply thin layer to affected area bid
    2. Doses should be at least 8 hours apart
    3. Avoid washing area for 4 hours after application
  5. Efficacy
    1. Modestly effective in reducing unwanted facial hair
    2. Hair Growth recurs soon after stopping medication
  6. References
    1. (2000) Med Lett Drugs Ther 42(1089):96 [PubMed]

Vaniqa (C0939525)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D000518
English vaniqa, Vaniqa, Women First Brand of Eflornithine Hydrochloride
Derived from the NIH UMLS (Unified Medical Language System)

You are currently viewing the original '\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree